Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals.

Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals.

老虎证券老虎证券2026/05/05 12:16
Show original
According to the terms of the agreement, Madrigal will pay Arrowhead a $25 million upfront payment, with the possibility of up to an additional $975 million in future payments based on research and development milestones. This collaboration involves Arrowhead's proprietary technology in the treatment of non-alcoholic steatohepatitis (NASH). Both parties will jointly advance the development of related therapies, and Arrowhead is expected to receive total revenue of up to $1 billion through the achievement of specific development, registration, and commercial milestones. This collaboration highlights the recognition of Arrowhead's technological strength in the field of RNA interference therapies within the industry.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth

Morgan Stanley analysts stated that Apple's upcoming "Surprise and Shine" autumn product launch event on September 9 may become the company's most important product release in nearly a decade.

智通财经2026/09/07 00:11
The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth